Acriflavine-Functionalized Silica@Manganese Ferrite Nanostructures for Synergistic Radiation and Hypoxia Therapies

ACS Appl Bio Mater. 2023 Aug 21;6(8):3089-3102. doi: 10.1021/acsabm.2c01021. Epub 2023 Jul 11.

Abstract

Mesoporous and nonmesoporous SiO2@MnFe2O4 nanostructures were loaded with the hypoxia-inducible factor-1 inhibitor acriflavine for combined radiation and hypoxia therapies. The X-ray irradiation of the drug-loaded nanostructures not only triggered the release of the acriflavine inside the cells but also initiated an energy transfer from the nanostructures to surface-adsorbed oxygen to generate singlet oxygen. While the drug-loaded mesoporous nanostructures showed an initial drug release before the irradiation, the drug was primarily released upon X-ray radiation in the case of the nonmesoporous nanostructures. However, the drug loading capacity was less efficient for the nonmesoporous nanostructures. Both drug-loaded nanostructures proved to be very efficient in irradiated MCF-7 multicellular tumor spheroids. The damage of these nanostructures toward the nontumorigenic MCF-10A multicellular spheroids was very limited because of the small number of nanostructures that entered the MCF-10A spheroids, while similar concentrations of acriflavine without nanostructures were toxic for the MCF-10A spheroids.

Keywords: drug delivery; hypoxia; magnetic mesoporous silica@MnFe2O4 nanoparticles; magnetic silica@MnFe2O4 nanoparticle acriflavine; multicellular tumor spheroids; radiation therapy.

MeSH terms

  • Acriflavine* / therapeutic use
  • Humans
  • Hypoxia / drug therapy
  • Nanostructures* / therapeutic use
  • Silicon Dioxide / chemistry

Substances

  • Acriflavine
  • manganese ferrite
  • Silicon Dioxide